2022
The Potential of N-acetyl Cysteine in Behavioral Addictions and Related Compulsive and Impulsive Behaviors and Disorders: a Scoping Review
Greenberg N, Farhadi F, Kazer B, Potenza M, Angarita G. The Potential of N-acetyl Cysteine in Behavioral Addictions and Related Compulsive and Impulsive Behaviors and Disorders: a Scoping Review. Current Addiction Reports 2022, 9: 660-670. PMID: 38362235, PMCID: PMC10868722, DOI: 10.1007/s40429-022-00446-3.Peer-Reviewed Original ResearchN-acetylcysteineSelf-injurious behaviorEffectiveness of NACEfficacy of NACSmall open-label trialsUse of NACCompulsive sexual behaviorOpen-label trialRepetitive self-injurious behaviorSexual behaviorCompulsive behaviorsGambling disorderGlutamate dysregulationBehavioral addictionsCase reportClinical trialsPreclinical studiesGlutamate homeostasisAcetyl cysteineDisordersMore studiesScoping ReviewCompulsive featuresAddictionImpulsive behaviorMechanistic Effects and Use of N-acetylcysteine in Substance Use Disorders
Greenberg N, Farhadi F, Kazer B, Potenza M, Angarita G. Mechanistic Effects and Use of N-acetylcysteine in Substance Use Disorders. Current Behavioral Neuroscience Reports 2022, 9: 124-143. DOI: 10.1007/s40473-022-00250-3.Peer-Reviewed Original ResearchSubstance use disordersN-acetylcysteineUse disordersEfficacy of NACTreatment of SUDsGlial glutamate transporter-1Glutamate transporter 1Drug-seeking behaviorCue-induced reinstatementNAC useAdjunctive useClinical studiesGlutamate homeostasisGlutamate signalingNeurobiological effectsClinical approachRelapse behaviorSubcortical regionsSynaptic plasticityFunctional connectivity networksPrefrontal cortexBehavioral interventionsTransporter 1Oxidative stressImpulsive behaviorEfficacy of neoadjuvant chemotherapy in male breast cancer compared with female breast cancer
Leone JP, Hassett MJ, Leone J, Tolaney SM, Vallejo CT, Leone BA, Winer EP, Lin NU. Efficacy of neoadjuvant chemotherapy in male breast cancer compared with female breast cancer. Cancer 2022, 128: 3796-3803. PMID: 36069365, PMCID: PMC9826058, DOI: 10.1002/cncr.34448.Peer-Reviewed Original ResearchConceptsPathologic complete responseFive-year OSNeoadjuvant chemotherapyMale breast cancerBreast cancerTumor subtypesOverall survivalIndependent associationEfficacy of NACInitiation of NACHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2National Cancer DatabaseGrowth factor receptor 2Multivariable logistic regressionFemale breast cancerFactor receptor 2HR-/HER2Complete responseMedian timeMultivariable analysisKaplan-MeierCancer DatabaseReceptor 2Logistic regressionBreast Cancer Patients: Who Would Benefit from Neoadjuvant Chemotherapies?
Yao L, Jia G, Lu L, Ma W. Breast Cancer Patients: Who Would Benefit from Neoadjuvant Chemotherapies? Current Oncology 2022, 29: 4902-4913. PMID: 35877249, PMCID: PMC9320700, DOI: 10.3390/curroncol29070389.Peer-Reviewed Original ResearchConceptsNeoadjuvant chemotherapyBreast cancer patientsCancer patientsEfficacy of NACHuman leukocyte antigen-DR isotypeInitiation of therapyTumor-infiltrating lymphocytesBenefits of treatmentTumor-associated macrophagesOncotype DXMolecular testingPatientsDecreased levelsCancer cellsChemotherapyTreatmentMammaPrintSurgeryLymphocytesTherapyTumorsMacrophages
2020
Efficacy of neoadjuvant chemotherapy (NAC) in male breast cancer (MaBC) compared with female breast cancer (FBC): A National Cancer Database (NCDB) study.
Leone J, Freedman R, Hassett M, Leone J, Tolaney S, Vallejo C, Leone B, Winer E, Lin N. Efficacy of neoadjuvant chemotherapy (NAC) in male breast cancer (MaBC) compared with female breast cancer (FBC): A National Cancer Database (NCDB) study. Journal Of Clinical Oncology 2020, 38: 587-587. DOI: 10.1200/jco.2020.38.15_suppl.587.Peer-Reviewed Original ResearchFemale breast cancerPathologic complete responseNeoadjuvant chemotherapyOverall survivalClinical responseTumor subtypesBreast cancerWorse OSExact testHuman epidermal growth factor receptor 2 (HER2) statusEpidermal growth factor receptor 2 statusEfficacy of NACInitiation of NACNational Cancer Database studyComplete clinical responseHormone receptor statusMale breast cancerLog-rank testFisher's exact testHR-/HER2Complete responseMedian ageReceptor statusMedian timeClinical stage
2016
N-Acetylcysteine in the Treatment of Pediatric Tourette Syndrome: Randomized, Double-Blind, Placebo-Controlled Add-On Trial
Bloch MH, Panza KE, Yaffa A, Alvarenga PG, Jakubovski E, Mulqueen JM, Landeros-Weisenberger A, Leckman JF. N-Acetylcysteine in the Treatment of Pediatric Tourette Syndrome: Randomized, Double-Blind, Placebo-Controlled Add-On Trial. Journal Of Child And Adolescent Psychopharmacology 2016, 26: 327-334. PMID: 27027204, PMCID: PMC6445198, DOI: 10.1089/cap.2015.0109.Peer-Reviewed Original ResearchConceptsBenefit of NACEfficacy of NACYale Global Tic Severity ScaleAttention-deficit/hyperactivity disorderObsessive-compulsive disorderTourette syndromeN-acetylcysteineObsessive-compulsive spectrum disordersSide effectsRecent placebo-controlled trialPediatric Tourette syndromePlacebo-controlled trialCurrent pharmacological treatmentsTreatment of ticsTotal tic scoreSeverity of ticsSubstantial side effectsTic Severity ScaleYears of ageMinimal side effectsPediatric TSPrimary outcomeSecondary outcomesGlutamatergic systemPharmacological treatment
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply